Results 101 to 110 of about 4,754 (217)
Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.
IntroductionLeishmaniasis is an important public health problem in the Americas. A Cochrane review published in 2009 analyzed 38 randomized controlled trials (RCT). We conducted a systematic review to evaluate the effects of therapeutic interventions for
Ludovic Reveiz +4 more
doaj +1 more source
Case summary A 12-year-old male neutered domestic shorthair cat underwent rhinoscopy due to inspiratory dyspnoea and stertor. Rhinoscopy showed signs of chronic rhinitis and a multinodular nasopharyngeal mucosa.
Rodolfo Oliveira Leal +5 more
doaj +1 more source
Advanced Technologies for Oral Controlled Release: Cyclodextrins for oral controlled release [PDF]
Cyclodextrins (CDs) are used in oral pharmaceutical formulations, by means of inclusion complexes formation, with the following advantages for the drugs: (1) solubility, dissolution rate, stability and bioavailability enhancement; (2) to modify the drug ...
A Al-Omar +153 more
core +1 more source
Treatment of Leishmania infantum Infections in Dogs
Dogs are reservoir hosts of the zoonotic parasite Leishmania infantum, the causative agent of canine leishmaniosis. Antiparasitic drugs that are commonly used in dogs include allopurinol, miltefosine, and meglumine antimoniate.
Melanie Kaempfle +2 more
doaj +1 more source
The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime®-Aventis Pharma Ltda.
Eliane de Morais-Teixeira +6 more
doaj +1 more source
Treatment of cutaneous leishmaniasis among travellers [PDF]
Leishmaniasis is endemic in 88 countries on five continents. There are 1-1.5 million cases of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in recorded cases over the last 10 years. Based on geographical distribution,
Beck, B. +4 more
core
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. [PDF]
UNLABELLED: Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide.
Croft, Simon L +3 more
core +2 more sources
Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence
We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations.
Juliana Saboia Fontenele e Silva +3 more
doaj +1 more source
Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis [PDF]
Introduction: The treatment of cutaneous leishmaniasis is toxic, has contraindications and a high cost. Objective: To estimate the cost-effectiveness of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. Methods:
Cardona-Arias, Jaiberth Antonio +3 more
core
Canine leishmaniosis (CanL) caused by Leishmania infantum is a zoonotic disease of global concern. Antileishmanial drug therapies commonly used to treat sick dogs improve their clinical condition, although when discontinued relapses can occur.
Marcos Ferreira Santos +16 more
doaj +1 more source

